Cargando…

Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response

Cross‐sectional imaging techniques are being increasingly used for disease evaluation in patients with multiple myeloma. Whole body magnetic resonance imaging (WB‐MRI) scanning is superior to plain radiography in baseline assessment of patients but changes following treatment have not been systemati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Latifoltojar, Arash, Hall‐Craggs, Margaret, Rabin, Neil, Popat, Rakesh, Bainbridge, Alan, Dikaios, Nikolaos, Sokolska, Magdalena, Rismani, Ali, D'Sa, Shirley, Punwani, Shonit, Yong, Kwee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Haematological Malignancy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244686/ https://www.ncbi.nlm.nih.gov/pubmed/27766627 http://dx.doi.org/10.1111/bjh.14401

Ejemplares similares

Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction
por: Latifoltojar, Arash, et al.
Publicado: (2017)

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2018)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

Multiple myeloma: patient outcomes in real‐world practice
por: Yong, Kwee, et al.
Publicado: (2016)

Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial
por: Lu, Jin, et al.
Publicado: (2017)

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial
por: Cook, Gordon, et al.
Publicado: (2019)

Sotatercept in patients with osteolytic lesions of multiple myeloma
por: Abdulkadyrov, Kudrat M, et al.
Publicado: (2014)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
por: Okawa, Yutaka, et al.
Publicado: (2008)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
por: Jagannath, Sundar, et al.
Publicado: (2018)

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
por: Hájek, Roman, et al.
Publicado: (2019)

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
por: Watanabe, Takashi, et al.
Publicado: (2016)

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients
por: Levin, Nancy, et al.
Publicado: (2016)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
por: Richardson, Paul G., et al.
Publicado: (2018)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
por: Kumar, Shaji, et al.
Publicado: (2017)

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
por: Jakubowiak, Andrzej J., et al.
Publicado: (2019)

Development of a prognostic model for overall survival in multiple myeloma using the Connect(®) MM Patient Registry
por: Terebelo, Howard R., et al.
Publicado: (2019)

Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd
por: Hughes, Timothy P., et al.
Publicado: (2017)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up
por: Ludwig, Heinz, et al.
Publicado: (2015)

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
por: Oostvogels, Rimke, et al.
Publicado: (2018)

Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population‐based study
por: Howell, Debra, et al.
Publicado: (2017)

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
por: Dimopoulos, Meletios A., et al.
Publicado: (2017)

The influence of baseline characteristics and disease stage on health‐related quality of life in multiple myeloma: findings from six randomized controlled trials
por: Robinson, Don, et al.
Publicado: (2016)

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
por: Brümmendorf, Tim H, et al.
Publicado: (2015)

Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study
por: Ishida, Takashi, et al.
Publicado: (2015)

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth
por: Dimopoulos, Meletios A., et al.
Publicado: (2017)

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
por: Sborov, Douglas W., et al.
Publicado: (2022)

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis
por: Gupta, Neeraj, et al.
Publicado: (2016)

Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging
por: Johnston, Edward William, et al.
Publicado: (2018)

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
por: Harrison, Simon J., et al.
Publicado: (2021)

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect(®) MM Registry
por: Abonour, Rafat, et al.
Publicado: (2020)

Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
por: McQuilten, Zoe, et al.
Publicado: (2022)

Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma
por: Chakraborty, Rajshekhar, et al.
Publicado: (2020)

Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients
por: Singh, Namrata, et al.
Publicado: (2020)

Identification of patients at high risk of secondary extramedullary multiple myeloma development
por: Stork, Martin, et al.
Publicado: (2021)

Whole body MRI in multiple myeloma: Optimising image acquisition and read times
por: Singh, Saurabh, et al.
Publicado: (2020)

Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
por: Biran, Noa, et al.
Publicado: (2021)

Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome
por: Xu, Jinglan, et al.
Publicado: (2008)

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
por: Oflazoglu, Ezogelin, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_bs10lu6vtp2in6fvjv323l7sa8